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Hype, hope and reflection
The touted transformative potential of stem cells, and their pivotal 
role in maintaining adult tissue homeostasis, has resulted in medical 
science shifting from a paradigm of repair to one of regeneration.[1] 
Regenerative cell therapy aims to add or replace human cells in order 
to regenerate tissue by using the intrinsic regenerative properties 
of the delivered cells. As a result, therapies utilising these highly 
regenerative units have been widely pursued in pre-clinical and 
clinical trials. Despite this, clinical applications, beyond the accepted 
utilisation of stem cells in the treatment of haematological diseases, 
have been relatively unsuccessful. This may be attributed to a number 
of aspects including poor engraftment and survival, inability of cells 
to differentiate into the target tissue, and the emerging understanding 
that, in many cases, an inflammatory or fibrotic host environment 
with underlying pathology deters the regenerative capacity of applied 
cells.[1,2] A further complication that hampers progress is that most 
clinical trials testing cellular regenerative therapies are undertaken 
in small cohorts and there is variability with regard to the type of 
stem cell population used, their method of delivery, formulation 
(combination of cellular and drug therapy), the level of control 
or randomisation, and even the outcome measures assessed.[1] To 
aggravate these issues, recent retractions by leading journals of 
previously lauded stem cell science and its clinical application,[3,4] as 
well as the proliferation of corrupt clinics exploiting the unrealistic 
hope of individuals seeking therapies for currently non-treatable 
diseases, threaten to sabotage this emerging area of regenerative 
medicine.[1]
It is therefore necessary to re-evaluate the current approach 
to regenerative medicine such that a realistic framework of 
expectations, related to developing clinical therapies, is established. 
Critical aspects to be considered include a clinical understanding of 
stem cell efficacy (based on data from completed clinical trials) as 
well as knowledge of the specific cellular microenvironment, and 
the underlying molecular mechanisms required for the success of 
cellular regenerative therapy.
Autologous stem cell therapies for 
non-congenital musculoskeletal 
disorders
Musculoskeletal disorders (MSDs) include a wide range of conditions 
that result from either trauma or degeneration and can affect the 
muscles, joints and skeleton; they include disabling conditions such 
as arthritis, chronic inflammatory diseases, autoimmune diseases, 
myopathies and osteoporosis (Table 1).[5]
Results of various clinical trials utilising stem cell therapy to treat 
MSDs have been published in the peer-reviewed literature (Fig. 1A). 
These trials are for the most part ongoing and are in a range of different 
phases, representing both uncontrolled (n=33) and controlled (n=28) 
trials; of the latter, 19 were randomised. A range of cellular delivery 
approaches were used including localised injection at the major 
site of the clinical disorder (therefore at least initially restricting 
administered cells to the affected area), stem cell infusion (injecting 
the cells into the systemic peripheral circulation) as well as the 
introduction of a physiological scaffold (Fig. 1A). Many clinical trials, 
including the transplantation of stem or stromal cells to stimulate 
the intrinsic repair mechanisms in the recipient tissue, appear in a 
comprehensive registry of clinical trials (Fig. 1B).[6] Others, such as 
autologous chondrocyte implantation (ACI) for the repair of cartilage 
defects, are available for clinical use.[7] However, in most cases these 
cellular therapies rely on allogeneic donor tissue. Allogeneic cells 
(both stromal and stem) sourced from young healthy donors have 
physiological, metabolic and genetic advantages when compared with 
those harvested autologously from either older individuals, where 
degenerative processes may persist, or from patients with underlying 
inflammatory conditions.[8] In the South African context, finding 
matching allogeneic donor stem cells for the purposes of regenerative 
therapy is, however, a challenge; this is due to a lack of resources and 
skilled personnel in the healthcare sector, poor and inequitable access 
to affordable cellular therapy and the high burden of disease.[9] In this 
context, autologous cell therapies may therefore offer a more feasible 
alternative. There are, however, currently no published study results 
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from trials, utilising autologous stem cells for the treatment of MSDs, 
that have successfully completed all four phases of clinical trials; 
this lack has contributed to the rise of extensive direct-to-patient 
marketing of unproven cellular therapies (Table 1).[1,10]
A search of the US National Library of Medicine’s clinical trials 
database (ClinicalTrials.gov; accessed 25 October 2018) using 
the search terms ‘musculoskeletal diseases or conditions’ AND 
‘autologous stem cell therapy’ yielded 80 results. This is, however, 
not a comprehensive list of ongoing studies as, despite the fact 
that clinical trials carried out in the United States are required to 
be registered, compliance is low and many trials are ultimately not 
registered. However, given that ClinicalTrials.gov is the largest trials 
registry, the selected 80 studies nevertheless provide an overview of 
current international trends in cell therapy for MSDs. Of these 80 
studies, 4 were excluded based on disease (cancer or genetic disorder) 
and therefore, for the purpose of the present review, the remaining 76 
studies were grouped together based on the type of musculoskeletal 
condition (Table 1; Fig. 1B). The majority of these clinical trials were 
performed in the context of autoimmune-related disorders such as 
rheumatoid arthritis, osteoarthritis and degenerative arthritis (n=48), 
followed by cartilage disorders (n=12), necrosis and osteomalacia 
(n=6), non-inherent dystrophy (n=3), tendon disorders (n=3) and 
non-inherent myopathy (n=2). Most of these studies are, however, in 
the early trial phases (Phase 1/2) with very little safety and efficacy 
data available; additionally, more than 60% of these studies focussed 
on inflammatory auto-immune conditions.
Stem cell populations residing within the bone marrow have shown 
the most promise as therapeutic agents and require very little, if any 
(in cases where stem cells are not affected by underlying disease), in 
vitro manipulation. These include heterogeneous cellular populations 
such as bone marrow (BM) aspirates, bone marrow mononuclear 
cells (BMMNs), mesenchymal stem cells (MSCs) and haematopoietic 
stem cells (HSCs; CD34+). Another heterogeneous cell population, 
not residing within the bone marrow, which also shows potential 
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n=48 1 13 18 10 1 1   4 2 withdrawn; 
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results 
available)
                       
Cartilage disorders                        







n=12 2   5 3 1     1 2 withdrawn; 
1 unknown 
status
4 (no results 
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Myopathy                        
 Myasthenia gravis; 
compartment 
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HSCs n=2   2             1 terminated 1 (no results 
available)
                       





MSCs, BM n=6   1 2 2     1     1 (no results 
available)
                       
Dystrophy                        
 Muscular dystrophy; 
Limb girdle 
dystrophy
MSCs, BMMNs n=3   3               2 (no results 
available)
Other                        
 Pseudo-arthrosis; leg 
length inequality 
MSCs, PRP n=2   1   1         1 suspended 1 (no results 
available)
MSC = mesenchymal stem cell; ADSC = adipose-derived stem cell; PRP = platelet-rich plasma; HSC = haematopoietic stem cell; SVF = stromal vascular fraction; BM = bone marrow; 
PBSC = peripheral blood stem cell; BMMC = bone marrow mononuclear cell.
Clinical trial phases: Early I – exploratory, no therapeutic or diagnostic goals; I – safety, adverse effects in healthy volunteers; II – preliminary, safety and effectiveness; III – larger populations, 
safety and effectiveness, dosages; IV – approval for marketing, safety, efficacy, optimal use. 
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for therapeutic use and is far more easily accessible, is the adipose 
tissue-derived stromal cell (ADSC) population from the stromal 
vascular fraction (SVF). However, a potential disadvantage of these 
ADSCs is the suggested higher rate of adverse events (AEs) when 
utilised in clinical trials.[11] The two clinical trials with results available 
(Table 1) were carried out by the same research group, using intra-
articular injection of autologous bone marrow-derived MSCs to treat 
knee osteoarthritis (NCT011832728 and NCT 01586312). Although 
these studies included a very small number of patients (n=12), the 
outcomes were positive, demonstrating functional improvement, 
pain relief and improved cartilage quality.[12,13] These results highlight 
the therapeutic potential of autologous bone marrow MSCs for 
localised conditions in the absence of systemic pathology.
Why regenerative mechanisms fail
Although the use of a patient’s own cells for therapeutic purposes 
is deemed to be preferable, the success of such autologous stem cell 
therapy is dependent on the medical history of the patient. Stem 
cells derived from patients with underlying pathologies such as 
chronic inflammatory (rheumatoid arthritis), degenerative (ageing, 
osteoporosis), metabolic (obesity, diabetes) and genetic (osteogenesis 
imperfecta, muscular dystrophy) disorders, are not as effective in 
promoting healing as those from healthy individuals.[2,8,14,15] This 
outcome is due, in part, to numerous pathological alterations in the 
niche microenvironment that may desensitise endogenous stem cells 
and alter their characteristics to such an extent that they cease to be 
regenerative agents.[2,15] For example, in a trial of autologous MSC 
therapy for osteonecrosis, 81% of patients displayed improvements 
in symptoms, whereas those without improvements had generally 
entered the trial at a more advanced stage of their disease, including 
a more severely hypoxic environment.[16] Despite the initial expansion 
of MSCs in an optimal ex vivo environment with adequate oxygen 
supply, hips with stage III or IV disease, with poor in vivo oxygen 
supply to the affected area, progressed. Therefore, systemic as well as 
local conditions may affect the efficacy of stem cell therapy, as stem 
cells may exhibit functional changes including impaired growth, 
differentiation and migratory capacity.[2,15,17]
A recent review of the literature, on the negative aspects of a range 
of diseases, indicates that stem cell dysfunction can occur as a result 
of genomic instability, telomere attrition, senescence, mitochondrial 
dysfunction, epigenetic changes or loss of proteostasis.[2] There is, 
furthermore, mounting evidence that the altered microenvironment, 
established as a result of the transition from health to chronic injury 
or disease, not only transforms intracellular characteristics, but also 
adversely affects cellular communication.[2,18] It has now become 
accepted that the regenerative potential of stem cells is mediated 
largely through their release of biologically active molecules, 
and the subsequent effect of these on target cells. Therefore, an 
understanding of such paracrine signalling in endogenous stem 
cell populations is likely to be at the epicentre of progress towards 
addressing their impaired regenerative capacity in the presence 
of underlying chronic disease.[19] For therapeutic applications 
of autologous stem cells, it is therefore essential that either the 
appropriate stem cell subpopulation (with retained regenerative 
properties) is used, or that the appropriate in vitro manipulation to 
correct stem cell function is performed prior to application. Such in 
vitro manipulation is not required to be at the level of gene therapy, 
but may include strategies such as antioxidant pre-conditioning.[18] 
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Fig. 1. Search strategy. Two separate search strategy approaches were applied. 1A. Database: www.ncbi.nlm.gov/pubmed; use of the terms ‘injection’, ‘infused’ 
and ‘scaffold’ did not yield a full breakdown of delivery methods. 1B. Database: www.clinicaltrials.gov; details of search results are presented in Table 1.
*Excluded because either stem cell therapy not mentioned, or musculoskeletal disease not mentioned.
†Or infused/re-infused: not all published papers sourced have been cited; further selection was based on relevance to text ClinicalTrials.gov, accessed 25 
October 2018.
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Alternatively, allogeneic stem cells from a healthy donor should be 
considered.
Therapeutic properties of stem cells
The multi-functional properties of stem cell populations include 
immune-modulatory, anti-inflammatory, growth-promoting and 
multi-lineage differentiation (bone, cartilage, muscle, adipose 
tissue) capabilities.[20,21] The paracrine properties of minimally 
manipulated stem cells are mediated through the release of growth 
factors, cytokines and microvesicles, the formation of tubules for 
mitochondria transfer, and/or the release of exosomes (small-sized 
extracellular vesicles containing miRNAs, lipids and proteins).[22,23] 
Although significant insight has been gained into the constituents 
of the secretome over the last few years, the complete secretome 
of the various populations of stem cells remains to be fully 
characterised and compared. A reference database for healthy 
stem cells, once established, can be used to assess patient-specific 
harvested stem cells prior to transplantation. What complicates this 
laudable goal is the fact that stem cells are extremely responsive to 
their microenvironments, and the slightest extracellular change can 
lead to modifications in stem cell gene expression and secretion 
of signalling biomolecules.[2,15,18] Hence, conditions for pre-
transplantation ex vivo assessment will need to be standardised 
carefully before extensive ex vivo expansion under more ideal 
conditions. The following three sections give a brief overview of 
which mechanisms are suspected to be crucial for therapeutic 
success under different disease conditions.
Autoimmune-related disorders
The potent immune-modulatory properties of MSCs in particular 
can be harnessed to treat autoimmune-related MSDs such as 
rheumatoid arthritis, osteoarthritis and degenerative arthritis. It has 
been shown that MSCs can prevent auto-immunity by inhibiting 
lymphocyte surveillance of tissues and T cell proliferation.[24,25] 
In addition to its effect on lymphocytes, the anti-inflammatory 
properties of MSCs function to alleviate persistent inflammation. 
Intra-articular injection of adipose-derived stem cells has been 
shown to be safe and efficacious in a number of recent clinical 
trials, particularly involving patients with osteoarthritis; despite the 
injection site being intra-articular, these cells may mediate their 
anti-inflammatory effects by increasing the number of circulating 
regulatory T cells and reducing the number of classically activated 
monocytes, thereby promoting a more anti-inflammatory global 
immune cell phenotype.[26-28] The MSC secretome contains various 
anti-inflammatory cytokines and RNAs that can modulate effector 
cell function.[21,23,25] The paracrine signalling of MSCs has been 
shown to stimulate the release of interleukin 10 (IL-10) from 
macrophages, and promote a macrophage phenotype switch from 
a destructive pro-inflammatory (M1 polarised macrophages) to a 
pro-regenerative anti-inflammatory (M2 polarised macrophages) 
phenotype.[29] This phenotype switch is a crucial step in any 
regenerative process, as it facilitates the transition from the 
inflammatory phase to the proliferative and remodelling stages 
of healing. Unfortunately, the anti-inflammatory ability of 
endogenous MSCs becomes compromised when they are exposed 
to chronic inflammation for extended periods,[2,15,18] thus limiting 
the effectiveness of autologous therapy under these conditions. 
Various strategies to ‘precondition or re-programme’ MSCs in vitro, 
in order to optimise cellular efficacy prior to transplantation, are 
currently being investigated in pre-clinical models. This includes 
the potential use of a combination of antioxidants (N-acetylcysteine 
and ascorbic-2-phosphate)[18] as well as other bio-active molecules 
to either mimic inflammatory stimuli or hypoxia.[30]
Tissue damage: tendons, non-inherent 
myopathies, acute injuries
The growth and regenerative properties of stem cells are relevant 
for tendon disorders, non-inherent dystrophy, myopathies and 
acute injuries. Skeletal muscle regeneration is complex and involves 
an intricate network of growth and extracellular matrix factor, 
cytokine and myogenic regulator factor signalling to regulate the 
activity of both tissue-resident muscle-specific stem cells (satellite 
cells) as well as non-myogenic progenitors.[31] When endogenous 
repair mechanisms fail, for example with unresolved inflammatory 
myopathies, these cells are either unable to facilitate repair or the 
parent pool of adult progenitors may have become depleted. In 
such instances, the inflammatory environment may be so severe 
that stem cells applied as therapy may fail to facilitate regeneration. 
However, the secretome of harvested exogenous stem or stromal 
cells can be applied to stimulate a reinstatement of intrinsic tissue 
repair mechanisms. Stem cell-derived growth factors that may 
mediate this include vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF1), 
transforming growth factor beta (TGFβ), basic fibroblast growth 
factor (bFGF) and the cytokines/chemokines granulocyte monocyte 
colony-stimulating factor (GM-CSF), monocyte chemotactic 
protein-1 (MCP1), interleukin-6 (IL6) and leukaemia inhibitory factor 
(LIF).[32] These represent a transient source of pro-differentiation 
signals for myoblasts and fibroblasts, known to reduce cellular 
apoptosis, promote survival, limit fibrosis and promote angiogenesis 
within the injured area.[31,32]
Cartilage and bone disorders
In the context of cartilage and bone disorders, researchers rely on 
the growth-promoting and multi-lineage differentiation capacity 
of stem cells to regenerate damaged tissue, whilst the immune-
modulatory paracrine functions prepare the microenvironment for 
healing.[33] In the context of fracture healing, the crosstalk between 
macrophages and MSCs is crucial for all three stages of bone healing, 
namely haematoma formation, inflammation, granulation tissue 
and callus formation.[34] Under normal conditions, macrophages 
regulate the recruitment and differentiation of MSCs via osteo-
inductive molecules such as oncostatin M (OSM), prostaglandin E2 
(PGE2) and bone morphogenic protein-2 (BMP2). MSCs also have 
an immunosuppressive impact on macrophages; this is mediated 
through the paracrine release of PGE2 and inducible nitric oxide 
synthase (iNOS) by MSCs.[34] Excessive M1 macrophage activity 
and impaired MSC function can, however, hamper osteogenesis 
and bone formation in certain disorders. Following regeneration, 
the structural and mechanical integrity of bone and cartilage is 
essential for regaining optimal strength and function. Biomaterials 
and scaffolds thus form key components of the therapeutic strategy 
and function as a delivery method for MSCs in these disorders. 
In addition to providing structure, bio-engineered scaffolds with 
a specific topography, porosity and the ability to release osteo-
inductive factors can dictate the differentiation of stem cells into a 
specific lineage.[35]
Towards a safe and efficacious cellular 
therapy
When considering the implementation of stem cell therapies in 
a clinical setting, due consideration should be given to existing 
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international guidelines that inform proper clinical trial and 
regulatory processes. Adverse effects (AEs), such as the long-term 
tumorigenicity of infused stem cells, remains a concern, especially 
since very few long-term follow-up data are available. In 2016, 
Centeno et al.[11] demonstrated that MSC-based percutaneous stem 
cell injections for the treatment of knee, hip, ankle/foot, hand/
wrist, elbow, shoulder or spine disorders, did not increase the risk 
for developing neoplasms in 2 372 orthopaedic patients in the first 
2 years post injections. However, a total of 325 adverse events were 
reported, of which 36 were classified as serious. The most common 
AE was post-procedure pain, with other less frequent AEs including 
neurological, vascular, allergic, immune, cardiac, infection and skin 
abnormalities. The authors indicated that bone marrow injections 
yielded the fewest AEs, and that the rate of AEs increased if other cell 
populations such as adipose tissue-derived stem cells were used or if 
the cells were cultured or manipulated in vitro prior to use.[11] Indeed, 
regulations guiding the application of adipose tissue-derived stem 
cells, and the definition of ‘minimally manipulated’, are currently a 
topic of debate.[36]
In an attempt to promote progress and optimise the clinical use of 
cell therapy for MSDs, a consensus was reached at the 2018 American 
Association for Orthopaedic Surgeons and National Institute of 
Health (AAOS/NIH U-13) conference, that osteoarthritis is the MSD 
with the most urgent need for clinical trial development.[37] This 
urgency is due to the substantial and progressive morbidity associated 
with osteoarthritis. To improve the accuracy of monitoring and 
standardisation, a first step was taken to create a framework for cell 
therapy, and clinical trial recommendations were made that included 
the establishment of high-quality patient registries and biorepository-
linked registries from both institutions and physicians that offer stem 
cell therapy.[37] Despite this progress towards establishing a relevant 
and consistent regulatory framework, it is clear that stem cell therapy 
is not yet a mature therapeutic option.
Summary and way forward
Despite the rapid growth in stem cell research over the last 20 years, 
and the expansion of our knowledge of these regenerative cells, 
disappointingly little clinical progress has been made. Significant 
extended therapeutic use, beyond standard practices available since 
the 1960s, remains elusive. What has, however, become increasingly 
clear is that, if autologous stem cells are to be used successfully in 
the field of regenerative medicine, the metabolic milieu that signals 
cellular changes and the mechanisms that execute the endpoint of 
improper stem cell function, must be identified and addressed as part 
of the regenerative strategy. With this knowledge, it will be possible to 
generate a conducive microenvironment which can ensure that these 
cells, whether from a healthy or pathological setting, can be guided 
towards a pro-regenerative phenotype. Subsequent controlled clinical 
trials can then determine the efficacy of this therapeutic approach, 
prior to release to the public.
In South Africa, the control and use of stem cells is regulated 
by the National Health Act (NHA); however, relevant guidelines, 
which would assist medical professionals, have yet to be made 
public by the National Department of Health.[38] In the absence of 
these, professional bodies such as the South African Transplantation 
Society (SATS) and the South African Stem Cell Transplantation 
Society (SASCTS) have established their own set of guidelines, 
which medical professionals can consult. Practitioners should be 
aware that approved stem cell therapies are currently limited to 
the treatment of blood and immunological disorders and should 
inform their patients accordingly. There are serious risks related to 
the use of allogeneic cells derived either from unknown sources or 
retrieved in the absence of Current Good Manufacturing Processes 
(CGMP); furthermore, their classification as ‘minimally manipulated’ 
is required when utilised autologously. Recent guidelines related 
to the latter can be found on the website of the Federal Drug 
Administration (FDA; https://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Tissue/). 
Finally, patients should be advised to participate only in registered 
clinical trials approved and regulated by accredited institutions and 
ethical committees.
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